NAVIX: Joining Forces to Revolutionize Vaccination Against Respiratory Infections
What if tomorrow’s vaccines could act at the very point where viruses enter the body? Through NAVIX, twelve French research teams are joining forces to develop a new generation of intranasal vaccines.
Coordinated by Dr Nathalie Mielcarek, Inserm Research Director and Deputy Director of the Lille Centre for Infection and Immunity (CIIL), the NAVIX project brings together twelve French research teams with a shared ambition: to develop innovative intranasal vaccination strategies against respiratory infections.
Supported by €14 million in funding over four years through the France 2030 programme, this multidisciplinary initiative combines expertise in immunology, virology, microbiology, and preclinical and clinical research.
By stimulating immune defenses directly at the respiratory mucosa, NAVIX aims to develop innovative vaccine platforms capable of targeting the earliest stages of infection and potentially reducing pathogen transmission.
Using influenza as an initial model, this nationwide collaboration seeks to establish adaptable vaccine technologies to address future infectious threats, including emerging respiratory pathogens.
-> See further
